66,719 Shares in Alumis Inc. $ALMS Bought by Blair William & Co. IL

Key Points

• Blair William & Co. IL has purchased 66,719 shares of Alumis Inc., valued at approximately $200,000, during the second quarter of the year.
• Several institutional investors have increased their stakes in Alumis, with Corebridge Financial Inc. raising its position by 53% in the first quarter.
• Alumis has received mixed ratings from analysts, with a current consensus rating of "Moderate Buy" and an average target price of $20.17.

Blair William & Co. IL purchased a new position in shares of Alumis Inc. (NASDAQ:ALMS - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 66,719 shares of the company's stock, valued at approximately $200,000. Blair William & Co. IL owned approximately 0.12% of Alumis at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Corebridge Financial Inc. raised its stake in Alumis by 53.0% during the 1st quarter. Corebridge Financial Inc. now owns 10,658 shares of the company's stock worth $65,000 after acquiring an additional 3,693 shares in the last quarter. Invesco Ltd. acquired a new stake in Alumis during the 1st quarter worth $164,000. Goldman Sachs Group Inc. raised its stake in Alumis by 24.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company's stock worth $378,000 after acquiring an additional 11,949 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Alumis by 12.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 127,854 shares of the company's stock worth $785,000 after acquiring an additional 14,453 shares in the last quarter. Finally, BML Capital Management LLC purchased a new position in Alumis during the 1st quarter worth $305,000.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Weiss Ratings reissued a "sell (e+)" rating on shares of Alumis in a research report on Wednesday, October 8th. Morgan Stanley lowered their price objective on shares of Alumis from $23.00 to $22.00 and set an "overweight" rating on the stock in a research report on Friday, August 15th. HC Wainwright reissued a "buy" rating and set a $14.00 price objective on shares of Alumis in a research report on Thursday, August 14th. Wall Street Zen raised shares of Alumis from a "strong sell" rating to a "hold" rating in a research report on Saturday, August 16th. Finally, Wells Fargo & Company assumed coverage on shares of Alumis in a research report on Friday, July 25th. They set an "overweight" rating and a $17.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Alumis presently has a consensus rating of "Moderate Buy" and an average target price of $20.17.

Alumis Stock Down 2.6%

Shares of NASDAQ:ALMS opened at $4.49 on Monday. The firm's 50-day simple moving average is $4.42 and its 200-day simple moving average is $4.37. Alumis Inc. has a fifty-two week low of $2.76 and a fifty-two week high of $13.11.

Alumis (NASDAQ:ALMS - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.06). The firm had revenue of $2.67 million for the quarter, compared to analyst estimates of $1.80 million. Equities research analysts expect that Alumis Inc. will post -8.51 EPS for the current fiscal year.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

Want to see what other hedge funds are holding ALMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alumis Inc. (NASDAQ:ALMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.